Parkinson’s cases may have nearly quadrupled since 1990. We asked UCSF neurologist Carlie Tanner, MD, PhD, what’s driving the surge. Aging and genes don’t explain all of it. Her research points to environmental toxicants as an important contributor.
The first personalized cancer vaccine to succeed in a late-stage trial was tested at UCSF. Earlier results showed it cut the risk of melanoma returning by nearly half. UCSF’s Adil Daud, MD, says it could work for other cancers too.
Meta just settled for $17.1 billion over concerns about children’s social media addiction. UCSF pediatrician and youth screen-time expert @jasonmnagata explains what the changes could mean for kids’ health and what parents should watch for.
After melanoma surgery, Mark Orwig joined a UCSF Health trial testing a personalized mRNA cancer vaccine to reduce the risk of melanoma returning. Federal research funding fueled the early mRNA science that made it possible — keeping Mark on the court. tiny.ucsf.edu/i9bINg
Mark Orwig, a 73-year-old tennis coach, joined 1,136 other skin cancer patients around the globe in testing intismeran autogene, an experimental treatment that drugmakers say is the most promising example of cancer vaccines built using messenger RNA. wapo.st/4cR9Tev
